ROCHESTER, NY, April 6, 2021 (GLOBE NEWSWIRE) – Document Security Systems, Inc. (“DSS” or the “Company”) (NYSE American: DSS), a multinational corporation operating businesses focused on brand protection technology , blockchain security, direct marketing, healthcare, real estate and securitized digital assets, today announced that its wholly-owned subsidiary Impact BioMedical, Inc. (“Impact BioMedical”) has received a notice of US Patent and Trademark Office (“USPTO”) acceptance (US 16/544 308) for a method of limiting the occurrence, reducing the risk or severity or treating Ebola and rhinovirus using of its exclusive compound Equivir. This allowance is in addition to the previously issued US patent by Equivir on influenza.
Equivir is designed to work by inhibiting virulence while blocking the multiple methods used by viruses to infect and replicate in host cells, after deployment in a vitamin-like fashion. Equivir is a novel blend of FDA-qualified, generally recognized as safe (GRAS) polyphenols that have been shown to have antiviral effects with potential applications as drugs or health supplements.
“This was one of our pending patents for Equivir, and we are very pleased to have expanded our Impact BioMedical intellectual property with this allocation,” said Frank D. Heuszel, CEO of DSS. “With broad antiviral application potential, Equivir could offer significant long-term value as we continue to assess and pursue development and partnership opportunities for this compound.”
Rhinovirus is the most common viral infectious agent in humans and is the leading cause of colds. Ebola, also known as Ebola virus disease (EVD) or Ebola hemorrhagic fever (EHF), is a rare but serious and often fatal disease in humans.
Equivir has demonstrated potential efficacy in in vitro studies on inhibiting viral infections and SARS COV2.
“Equivir was designed to combat emerging viral epidemics and pandemics. It is specifically created as a broad spectrum antiviral for epidemics such as influenza. We are continuing our research to use Equivir as an easily deployable strategic defense against viral infections.” commented Daryl Thompson, Director of Scientific Initiatives at Impact BioLife and founder of the advanced research company GRDG Sciences, LLC (“GRDG”). Impact BioLife is a wholly-owned subsidiary of Impact BioMedical.
GRDG Chief Scientific Advisor Dr Roscoe M. Moore, Jr., U.S. Assistant Surgeon General (Retired) and Former Outbreak Intelligence Service (EIS) Officer at the U.S. Center for Control and disease prevention, said, “While the threat of viral infections remains significant, Equivir’s ability to be deployed quickly is a working solution towards global public health. “
Impact BioMedical received its first Equivir patent (US 10,383,842) from the USPTO on August 20, 2019. A third Equivir patent is pending.
About Impact BioMedical, Inc.
Impact BioMedical, Inc. (“Impact BioMedical”) is a wholly owned subsidiary of DSS and a unique technology source, developer and business partner to address unmet human health and wellness needs. For more information on Impact BioMedical, visit http://impbio.com/.
About Document Security Systems, Inc.
DSS is a multinational corporation operating businesses focused on brand protection technology, blockchain security, direct marketing, healthcare, real estate and securitized digital assets. Its business model is based on a distribution-sharing system in which shareholders will receive shares from its subsidiaries as DSS strategically transforms them into IPOs. Its historical activity revolves around counterfeit deterrence and authentication technologies, smart packaging and consumer product engagement. DSS is led by its President and largest shareholder, Mr. Fai Chan, a very successful global business veteran for over 40 years, specializing in business transformation while managing risk. He has successfully restructured more than 35 companies with a combined value of $ 25 billion.
For more information on DSS, visit http://www.dsssecure.com.
Dave Gentry, CEO
RedChip Companies Inc.
Safe Harbor Disclosure
This press release contains forward-looking statements which are made in accordance with the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as as modified. These forward-looking statements include, but are not limited to, statements relating to the company’s intended use of the product and other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which could cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include: risks relating to our growth strategy; our ability to secure, execute and maintain funding and strategic agreements and relationships; risks related to the results of development activities; our ability to attract, integrate and retain key personnel; our need for substantial additional funds; patent and intellectual property issues; competition; as well as other risks described in the section entitled “Risk Factors” of the prospectus and in our other documents filed with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q , all of which can be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made and reflect management’s current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or commitment to publicly release any update or revision to any forward-looking statement contained herein to reflect any change in our expectations or any change in the events, conditions or circumstances upon which such statement is based, except if necessary. by the law.
News powered by iR Direct –
Copyright © 2021 Issuer Direct Corporation.
All rights reserved.